This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
VEEV Q2 Earnings & Revenues Beat Estimates, Margin Rises, Stock Up
by Zacks Equity Research
Veeva Systems' second-quarter earnings and revenues beat estimates, margins expand and raised FY26 outlook lifts shares higher.
DGX Stock Gains Following a New Joint Venture With Corewell Health
by Zacks Equity Research
Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio?
by Zacks Equity Research
TMO's growth, driven by new partnerships and strong end markets, faces challenges from macro pressures and fierce competition.
PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
Phibro Animal Health posts strong Q4 earnings and revenues, fueled by Animal Health growth. Meanwhile, the gross margin contracts.
Should You Add Zimmer Biomet Stock to Your Portfolio Now?
by Zacks Equity Research
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
by Zacks Equity Research
Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
by Sridatri Sarkar
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
Should You Add IDEXX Stock to Your Portfolio Right Now?
by Zacks Equity Research
IDXX gains from strong CAG Diagnostics growth and rising cloud software demand, but debt levels remain a concern for investors.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD's growth drivers - AirSeal, Buffalo Filter, BioBrace, and Foot & Ankle - are offsetting tariffs and supply risks, making the stock worth retaining.
Is it the Right Time to Hold Labcorp Stock in Your Portfolio?
by Zacks Equity Research
LH witnesses growth in specialty testing and strategic acquisitions, but macro and currency headwinds remain a concern.
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
by Zacks Equity Research
NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.
IDEXX Gains 56.2% in a Year: What's Driving the Rally?
by Zacks Equity Research
IDXX shares surge 56.2% in a year, fueled by strong diagnostics growth, cloud software gains and an upbeat 2025 outlook.
HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?
by Moumi Mondal
Two MedTech giants, one clear winner. Boston Scientific's momentum outpaces Hologic's cautious rise.
BWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care
by Zacks Equity Research
BrainsWay's $5 million investment in Neurolief expands its mental health footprint with at-home depression treatment potential.
Boston Scientific (BSX) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet Gains 77.2% in a Year: What's Driving the Rally?
by Zacks Equity Research
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Should Boston Scientific Stock Be in Your Portfolio Right Now?
by Zacks Equity Research
BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
by Nalak Das
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
by Zacks Equity Research
MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
by Zacks Equity Research
ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
Should Quest Diagnostics Stock Be in Your Portfolio Right Now?
by Zacks Equity Research
DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.
Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges
by Zacks Equity Research
ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.
Teleflex Stock Gains Following Barrigel's Launch in Japan
by Zacks Equity Research
TFX stock jumps 3.7% after launching Barrigel in Japan, marking a milestone in its global expansion strategy.
Masimo Shares Dip Despite FDA Clears Expanded Use of O3 Monitoring
by Zacks Equity Research
MASI gains FDA clearance to expand O3 monitoring with delta hemoglobin parameters across all patient groups.
PAHC vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?